Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
|Articles|October 27, 2021
Daily Medication Pearl: Apremilast (Otezla)
Author(s)Saro Arakelians, PharmD
Apremilast is indicated for the treatment of psoriatic arthritis, plaque psoriasis, and oral ulcers associated with Behçet disease.
Advertisement
Medication Pearl of the Day: Apremilast (Otezla)
Indication: Apremilast, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of adult patients with active psoriatic arthritis; adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy; and adult patients with oral ulcers associated with Behçet’s disease.
Insight:
- Dosing: To reduce the risk of gastrointestinal symptoms, titrate to recommended dose of 30 mg twice daily from 10 mg, once a day, to twice a day, then 20 mg, then 30 mg within 6 days.
- Dosage form: Tablets 10 mg, 20 mg, and 30 mg.
- Adverse events (AEs): The most common AEs (≥ 5%) are diarrhea, nausea, headache, and upper respiratory tract infection.
- Mechanism of action:Apremilast is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels.
- Manufacturer: Amgen
Sources:
Advertisement
Related to this article
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
Garlic has a long history in traditional medicine, but evidence for its benefits varies by preparation, and patients taking medications that increase bleeding risk should use it with caution.
About 89% of Americans live within 5 miles of a pharmacy, but proximity says little about whether they can afford their medications or get real counseling.
The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.
Getting patients vaccinated matters more than which COVID-19 vaccine they receive, says Jodi Longueil, PharmD.
The new agreement lets Hims & Hers patients obtain FDA-approved tirzepatide and orforglipron at Lilly’s self-pay prices.
The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Oral PCSK9 Inhibitor Enlicitide Sustains LDL-C Reductions
2
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
3
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumor
4
Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care
5